[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
June 13, 2001

Postmenopausal Hormone Therapy for Prevention of FracturesHow Good Is the Evidence?

Author Affiliations

Author Affiliations: Department of Epidemiology and Biostatistics and Department of Medicine, University of California, San Francisco.

JAMA. 2001;285(22):2909-2910. doi:10.1001/jama.285.22.2909

Estrogen has been used for many years to prevent bone loss and fractures in postmenopausal women. Support for this practice comes from 2 lines of evidence. First, observational studies consistently suggest that postmenopausal hormone therapy reduces the risk of hip and other types of fracture.1,2 However, observational studies are susceptible to selection bias and confounding. This may be especially true of studies of hormone therapy because users tend to be healthier, wealthier, and more active than nonusers.3 Even if observational studies are qualitatively correct, they may overestimate the degree of risk reduction attributed to hormone therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×